TGA approves first oral GLP-1 weight-loss pill Foundayo for Australian market
The Therapeutic Goods Administration has authorized the oral GLP-1 medication Foundayo, developed by Lilly, for weight loss and type 2 diabetes treatment, with availability expected within days.
The Therapeutic Goods Administration has granted approval for Foundayo, an oral GLP-1 medication, to be prescribed in Australia for weight management and type 2 diabetes. The daily pill, described by Lilly as a first-of-its-kind small-molecule GLP-1 that can be taken at any time without food or water restrictions, is expected to reach pharmacies within days of the ruling.
Samantha Hocking, president of the National Association of Clinical Obesity Services, said the clearance could help address the country's rising obesity rates, which affect about 13 million adults. She noted that obesity is a chronic disease linked to a range of serious conditions, including cancer, cardiovascular disease and type 2 diabetes, and emphasized the need for stronger prevention and broader access to proven treatments.
Lilly Australia highlighted that clinical trials for Foundayo involved more than 10,000 participants across 15 countries, including collaborations with Australian hospitals and clinics. General Manager Dr Manny Simons said the company will now focus on expanding access for Australians who may benefit from the new medicine.
Foundayo will be available through private prescription but has not yet been listed on the Pharmaceutical Benefits Scheme. Lilly warned that concurrent use with other GLP-1 drugs is not recommended and listed common digestive-system side effects, which were generally mild to moderate and tended to lessen after dose escalation. The company also cautioned about risks of low blood sugar when combined with insulin or sulfonylureas, pancreatitis, and contraindications for pregnancy or hypersensitivity to the drug's ingredients.